This study is in progress, not accepting new patients
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Aravive, Inc.
- ID
- NCT04729608
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 350 study participants
- Last Updated